Mimetogen Pharmaceuticals USA, Inc.
Quick facts
Phase 3 pipeline
- MIM-D3 Ophthalmic Solution · Ophthalmology
MIM-D3 Ophthalmic Solution is a small molecule that targets the rhodopsin kinase (GRK1) to treat retinal diseases. - Tavilermide ophthalmic solution · Ophthalmology
Tavilermide is a small-molecule integrin antagonist that inhibits cell adhesion and migration by blocking integrin-mediated interactions, reducing inflammatory cell infiltration in ocular tissues.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: